Sionna Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael Cloonan
- Full Time Employees
- 59
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 21 Hickory Drive Suite 500 Waltham MA United States of America 02451
- IPO Date
- Feb 7, 2025
- CIK
- 0002036042
- Website
- sionnatx.com
- Similar Companies
- Business
- Sionna Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for diseases caused by dysregulation of RNA. The company’s core products and services include the discovery and development of small molecule and RNA-targeted therapeutics designed to modulate RNA splicing and improve gene expression. Sionna Therapeutics utilizes proprietary RNA-targeting platforms to create treatments for genetically defined patient populations, primarily in the areas of neurology, ophthalmology, and other rare diseases. The company operates primarily in the United States and internationally as it advances its pipeline through clinical trials. Founded in 2018, Sionna Therapeutics is headquartered in Cambridge, Massachusetts. Recent major company developments include strategic collaborations and advancements in its drug pipeline with a focus on moving lead candidates into clinical stages. Sionna has also expanded its research capabilities through partnerships and has progressed new product candidates into early clinical trials within the last one to two years. These steps emphasize Sionna’s commitment to translating its platform technology into novel therapeutic candidates addressing unmet medical needs in precision RNA medicine. The company continues to broaden its presence in biopharmaceutical innovation through strategic alliances and operational growth consistent with its mission to develop RNA-targeted therapies. Sionna Therapeutics operates within the biotechnology and pharmaceutical industry segments, targeting patients with rare and serious diseases caused by RNA splicing errors. Its customer base includes research institutions, healthcare providers, and ultimately patients requiring advanced precision medical treatments. It functions independently and may engage in collaborations with larger pharmaceutical firms to leverage its RNA-focused technologies. The company’s geographic footprint spans the US and global markets through clinical development and research partnerships.
Company News
Sionna Therapeutics, Inc. (SION) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
Sionna Therapeutics, Inc. (NASDAQ:SION) Stock Has Average Target Price of $42.33 According to Brokerages
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
These beaten-down stocks could bounce back in January, if history is any guide
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down
Brokerages Set Sionna Therapeutics, Inc. (NASDAQ:SION) Price Target at $42.22
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm